Drug Trial Radar · NCT00490971
A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder
Last checked: Nov 19, 2026Latest source record: Apr 15, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
768
Actual
Start
May 2006
Primary completion
Apr 2010
Study completion Apr 2010
Sponsor
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jun 25, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effectiveness and safety of oral extended-release (ER) paliperidone compared with placebo in the prevention of the recurrence of mood symptoms in patients with Bipolar I Disorder who initially respond to treatment of an acute manic or mixed episode with paliperidone ER. Olanzapine was included as an active control arm, although the study is not designed to allow for a direct comparison of olanzapine with paliperidone.
Conditions
- Bipolar Disorder
Interventions
OlanzapineDrug
Once daily in dose range of 5 to 20 mg/day for 15 weeks, then until recurrence
Paliperidone ERDrug
Once daily in dose range of 3 to 12 mg/day for 15 weeks, then until recurrence
PlaceboDrug
Once daily until recurrence (only after initial 15 weeks on paliperidone ER)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Recurrence of Any Mood Symptoms (Manic or Depressive) Associated With Bipolar I DisorderTime frame: Date of randomization into the maintenance phase until the first occurrence of recurrence of any symptoms or discontinuation from the study, assessed over a period of 41 months.
Locations
78 sites in 16 countries. Site status is shown where the registry gives one.
Site not named
Scottsdale, Arizona
Site not named
Riverside, California
Site not named
San Diego, California
Site not named
Jacksonville, Florida
Site not named
Honolulu, Hawaii
Site not named
Chicago, Illinois
Site not named
Hoffman Estates, Illinois
Site not named
Wichita, Kansas
Site not named
New Orleans, Louisiana
Site not named
Willingboro, New Jersey
Site not named
Cincinnati, Ohio
Site not named
Lyndhurst, Ohio
Site not named
Philadelphia, Pennsylvania
Site not named
Arlington, Texas
Site not named
Austin, Texas
Site not named
Bellevue, Washington
Site not named
Bulgaria, Bulgaria
Site not named
Radnevo, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Baoding, China
Site not named
Beijing, China
Site not named
Guangzhou, China
Site not named
Nanjing, China
Site not named
Shanghai, China
Site not named
Suzhou, China
Site not named
Xi'an, China
Site not named
San José, Costa Rica
Site not named
Casablanca, France
Site not named
Manouba, France
Site not named
Berlin, Germany
Site not named
Bochum, Germany
Site not named
Chemnitz, Germany
Site not named
Düsseldorf, Germany
Site not named
Göttingen, Germany
Site not named
Jena, Germany
Site not named
Lübeck, Germany
Site not named
Bangalore, India
Site not named
Calicut, India
Site not named
Coimbatore, India
Site not named
Hyderabad, India
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.